• Forsythoside E: A Translational PKM2 Strategy

  2026-09-05

  Forsythoside E offers a mechanistically differentiated route into immunometabolic research by promoting PKM2 tetramerization, reducing macrophage glycolysis, and interrupting PKM2–STAT3 signaling. This article translates those findings into practical study design, competitive positioning, and a disciplined path toward sepsis-induced liver injury research.

• Isorhamnetin Oocyte Maturation Workflow

  2026-09-04

  Build a mechanism-oriented oocyte maturation workflow with Isorhamnetin, combining polar body extrusion, ROS, apoptosis, endoplasmic reticulum, and PI3K/Akt readouts. This guide emphasizes solvent control, dose selection, and troubleshooting so the compound functions as more than a generic antioxidant.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-04

  The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia (AML) cell growth and survival. By combining gene knockdown, interaction proteomics, RNA-seq, ChIP-seq, and in vivo validation, the authors connect LDB1-dependent transcriptional regulation with apoptosis-related gene control and propose the complex as a potential therapeutic vulnerability.

• SB-3CT Workflows for MMP-9 and ECM Research

  2026-09-03

  Use SB-3CT to connect gelatinase activity with extracellular-matrix remodeling in tumor, vascular, and neural models. This practical guide emphasizes concentration-aware assay design, perineuronal-net workflows, and controls that distinguish MMP-2 effects from MMP-9 biology.

• Forsythoside E: PKM2 Workflow for Macrophages

  2026-09-03

  Forsythoside E connects PKM2 tetramerization with macrophage metabolism, STAT3 signaling, and inflammatory liver injury models. This practical guide covers dose design, orthogonal validation, in vivo translation, and troubleshooting for reproducible immunometabolism workflows.

• Lyso-Tracker Red for Nanoparticle Lysosome Assays

  2026-09-02

  Use Lyso-Tracker Red to connect nanoparticle uptake with lysosomal acidification, distribution, and escape in living immune cells. This practical workflow translates vaccine-adjuvant findings into reproducible fluorescence microscopy and flow-cytometry assays while emphasizing controls that prevent overinterpretation.

• PstS-1 Nanobody for Tuberculosis Molecular Imaging

  2026-09-02

  Dhekale et al. isolated the C8 nanobody against the Mycobacterium tuberculosis phosphate-binding protein PstS-1 and demonstrated its reactivity with bacilli-associated and macrophage-associated antigen. The findings support C8Nb as a candidate molecular-imaging probe, while also highlighting the need for validation in authentic granulomas and human disease settings.

• Anagliptin (SK-0403): DPP-4 and Vascular Research

  2026-09-01

  Anagliptin (SK-0403) is a selective, orally active DPP-4 inhibitor used in diabetes and metabolic research. In rabbit aortic rings, published evidence links its vasorelaxation to Kv channel activation and SERCA pump function, rather than endothelial or cyclic-nucleotide signaling.

• BV6 as a Cell-Death Discriminator in Cancer Research

  2026-09-01

  BV6 is an IAP antagonist that can expose weaknesses in tumor-cell survival signaling. This article explains how lysoptosis research can sharpen apoptosis, radiosensitization, and combination-assay interpretation.

• Sodium phosphate dibasic for assay workflows

  2026-08-31

  Sodium phosphate dibasic (Na2HPO4) provides practical pH control for protein, enzyme, molecular biology, and aquatic toxicity assays. This guide connects buffer design with species-sensitive sulfamonomethoxine testing, emphasizing matrix controls, reproducible preparation, and troubleshooting.

• Tamsulosin for Preventing Postoperative Urinary Retention

  2026-08-31

  This systematic review and meta-analysis pooled 23 randomized controlled trials to evaluate whether perioperative Tamsulosin reduces postoperative urinary retention. Across 22 quantitatively analyzed studies, Tamsulosin halved the relative risk of retention and increased maximum urinary flow rate, while effects on surgery duration, urinary symptoms, quality of life, and urinary tract infection were not significant.

• Temafloxacin Combinations Against Mycobacterium avium

  2026-08-30

  The 1993 reference study integrated extracellular susceptibility testing with an intracellular macrophage model to assess clarithromycin, temafloxacin, and ethambutol against clinical Mycobacterium avium strains. Its main practical finding was that combination activity was strain-dependent, while the three-drug regimen produced the strongest intracellular bactericidal effect.

• Cathepsin B and L Proteases in Barley Senescence

  2026-08-29

  Schepetkin and Fischer integrated substrate profiling, pH dependence, inhibitor assays, activity-based labeling, and immunoblotting to characterize proteolysis during developmental senescence in barley leaves. Their findings indicate that cathepsin L-like and related papain-like cysteine proteases make a major contribution to protein recycling, while cathepsin B-like activity is detectable but less dominant under the tested conditions.

• Tropisetron Beyond 5-HT3: A Translational Playbook

  2026-08-28

  Tropisetron Hydrochloride is more than a 5-HT3 receptor probe. Its dual receptor pharmacology and reported OCT2/MATE1 transporter interactions create a practical framework for neuroscience receptor modulation, serotonin signaling research, and translational drug–drug interaction studies.

• SGC-CBP30 for CREBBP/EP300 Research

  2026-08-28

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for testing transcriptional coactivator dependence in chromatin, cancer, and epigenetics research. This guide translates super-enhancer and TGF-β/SMAD3 findings in lung adenocarcinoma into practical treatment, reporter, chromatin, and troubleshooting workflows.

8164 records 3/545 page Previous Next 12345 下5页 Last page